3.150USD+3.150After-hours 07/31, 20:00 (ET)
27.67KMarket Cap
LossP/E TTM
Key Figures
3.200Open
3.340High
15.52KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
177.78%Turnover Ratio
3.280Prev. Close
3.150Low
26.99KTurnover
LossP/E Static
0.00P/B
0.00%Div Yield TTM
-105.48%ROA
36.40052wk High
0.51Volume Ratio
-7.88MNet Profit
8.73KShares
-1791.0240EPS TTM
1.09Beta
-178.24%ROE
2.95052wk Low
5.79%Amplitude
100.00%Gross Margin
27.67KMarket Cap
-3.02Reward/Risk
5.34%Risk Rate
Currency: USD Updated: 2026-07-30 Key Insights
Can Fite Biopharma Ltd's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 103 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.00.In the medium term, the stock price is expected to remain stable.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Can Fite Biopharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Can Fite Biopharma Ltd Highlights
StrengthsRisks
Can Fite Biopharma Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Can Fite Biopharma Ltd
CANF
1
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Can Fite Biopharma Ltd Info
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Ticker SymbolCANF
CompanyCan Fite Biopharma Ltd
CEOFishman (Pnina)
Websitehttps://www.canfite.com/
Shareholders
FAQs
What is the current price of Can Fite Biopharma Ltd (CANF)?
The current price of Can Fite Biopharma Ltd (CANF) is 3.17.
What is the symbol of Can Fite Biopharma Ltd?
The ticker symbol of Can Fite Biopharma Ltd is CANF.
What is the 52-week high of Can Fite Biopharma Ltd?
The 52-week high of Can Fite Biopharma Ltd is 36.40.
What is the 52-week low of Can Fite Biopharma Ltd?
The 52-week low of Can Fite Biopharma Ltd is 2.95.
What is the market capitalization of Can Fite Biopharma Ltd?
The market capitalization of Can Fite Biopharma Ltd is 27.67K.
Is Can Fite Biopharma Ltd (CANF) currently rated as Buy, Hold, or Sell?
According to analysts, Can Fite Biopharma Ltd (CANF) has an overall rating of Buy, with a price target of 50.00.
What is the Earnings Per Share (EPS TTM) of Can Fite Biopharma Ltd (CANF)?
The Earnings Per Share (EPS TTM) of Can Fite Biopharma Ltd (CANF) is -1791.02.
